Professor Robert Hills
Professor of Medical Statistics
Robert Hills studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity. He joined the CTSU in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2018, he moved back to the University of Oxford where he is part of the Early Breast Cancer Trialists' Collaborative Group.
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Marquis M. et al, (2019), Blood Cancer J, 9
Real world data and the art of maintenance therapy.
Hills RK., (2019), Br J Haematol, 184, 493 - 494
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Burnett AK. et al, (2018), Leukemia, 32, 2693 - 2714
Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials
Hills RK. et al, (2018), BLOOD, 132
Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) - the UK Monocle Study
Knapper S. et al, (2018), BLOOD, 132